1Y Close · As of Aug 26, 2026
KUKJEON operates in the Pharmaceuticals sector.
Legal name: KUKJEON Co.,Ltd
In fiscal year 2025, KUKJEON (307750) reported revenue of 131.0 billion KRW, down 4.0% from 136.5 billion KRW a year earlier.
Operating profit was -2.6 billion KRW and net income was -4.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 125.5 billion KRW, with a P/B of 1.31.
These figures can be verified in the DART filing (receipt no. 20260323001002).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 131.0B | -2.6B | -4.8B |
| 2024 | 136.5B | 368M | 538M |
| 2023 | 122.0B | 6.5B | 4.7B |
| 2022 | 103.7B | 3.5B | 8.9B |
| 2021 | 85.4B | 6.1B | 4.0B |
Recent Filings
Early BW Acquisition (Including Overseas BW)
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Early BW Acquisition (Including Overseas BW) |
| 2026-08-24 | Large Shareholding Report (General) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-13 | Large Shareholding Report (General) |